Transcription of CT authorisation in the EU: present and future
{{id}} {{{paragraph}}}
Example: marketing
CT authorisation in the EU: present and future
CT authorisation in the EU: present and future Karl Broich, BfArM. Karl Broich | CT authorisation in the EU: present and future | 09 March 2018 | Page 1. Contents Clinical Trials in the EU. Clinical Trials under Regulation (EU) No. 536/2014. Transition period from Directive to Regulation Clinical Trials Portal & Database programme Current & future challenges for the NCAs Conclusions Karl Broich | CT authorisation in the EU: present and future | 09 March 2018 | Page 2. Clinical Trials in Europe: What is new? Clinical Trials in the EU what has changed over time? Before May 2004 Directive 2001/20/EC Regulation (EU) No. 536/2014. (since 1 May 2004) (published May 2014). National rules, different First step to harmonise processes full harmonisation and combined processes/requirements for and requirements for clinical trial assessment of multinational trials authorisations (after full functionality of the EU.)
Introduction of e -application form …Before May 2004. National rules, different processes/requirements for authorisation in each EU Member States …resulted in delays and complications …Regulation (EU) No. 536/2014 (published May 2014) Full harmonisation and combined assessment of multinational trials (after full functionality of the EU
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Initial (full) marketing authorisation, Initial (Full) Marketing Authorisation application, Initial, Initial Marketing Authorisation, Authorisation, Data Integrity Definitions and Guidance for, Marketing author isation application, CONSOLIDATED VERSION OF DIRECTIVE, Harmonised Technical Guidance for Non